These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19946789)

  • 21. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
    Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
    Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?
    Yamaki J; Lee M; Shriner KA; Wong-Beringer A
    Diagn Microbiol Infect Dis; 2011 May; 70(1):124-30. PubMed ID: 21392923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.
    Welsh KJ; Abbott AN; Lewis EM; Gardiner JM; Kruzel MC; Lewis CT; Mohr JF; Wanger A; Armitige LY
    J Clin Microbiol; 2010 Mar; 48(3):894-9. PubMed ID: 20089758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
    Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
    JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
    Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy.
    Gasch O; Camoez M; Dominguez MA; Padilla B; Pintado V; Almirante B; Molina J; Lopez-Medrano F; Ruiz E; Martinez JA; Bereciartua E; Rodriguez-Lopez F; Fernandez-Mazarrasa C; Goenaga MA; Benito N; Rodriguez-Baño J; Espejo E; Pujol M;
    Clin Microbiol Infect; 2013 Nov; 19(11):1049-57. PubMed ID: 23331461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
    Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
    Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of molecular typing, vancomycin MIC, and clinical outcome for patients with methicillin-resistant Staphylococcus aureus infections.
    Chen CP; Liu MF; Lin CF; Lin SP; Shi ZY
    J Microbiol Immunol Infect; 2017 Oct; 50(5):619-626. PubMed ID: 26497450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
    Lodise TP; Graves J; Evans A; Graffunder E; Helmecke M; Lomaestro BM; Stellrecht K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3315-20. PubMed ID: 18591266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
    Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
    Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
    Takesue Y; Nakajima K; Takahashi Y; Ichiki K; Ishihara M; Wada Y; Tsuchida T; Uchino M; Ikeuchi H
    J Infect Chemother; 2011 Feb; 17(1):52-7. PubMed ID: 20625789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.